Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2022-10-31 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document text is a short announcement dated October 31, 2022, detailing a change in the total number of outstanding shares and votes following the issuance of new C-shares related to employee incentive programs (Board SHP 2022 and Co-worker LTIP 2022). This directly concerns the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital structure changes. It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). The length is short (3130 chars), but the content is a direct notification of a capital change, making SHA more specific than a general RPA or RNS.
2022-10-31 Swedish
Oncopeptides fas 3-studie LIGHTHOUSE bekräftar ytterligare kliniska nyttan med melflufen
Earnings Release Classification · 1% confidence The document is a press release dated October 26, 2022, originating from Oncopeptides AB. It announces positive data from their Phase 3 clinical trial, LIGHTHOUSE, regarding the drug melflufen for treating multiple myeloma. The text details trial design, primary endpoints (PFS), statistical results (HR, p-values), quotes from investigators and the CEO, and provides background information on the drug and the disease. This format—a formal announcement of clinical trial results and associated regulatory/commercial context—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is specifically announcing the results of a clinical study and providing context, it aligns best with an Earnings Release (ER) which often includes key operational and clinical updates, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure without the typical ER structure. However, the structure strongly suggests a formal press release intended for investors and the public announcing key performance/development milestones, which is the primary function of an ER, even if the content is clinical data rather than quarterly financials. Given the options, ER is the most appropriate fit for a major clinical data announcement press release. FY 2022
2022-10-26 Swedish
Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen
Regulatory Filings Classification · 1% confidence The document is a press release dated October 26, 2022, announcing data from the phase 3 LIGHTHOUSE study regarding the drug melflufen for multiple myeloma. It details study design, endpoints (PFS, ORR, OS), patient numbers, and quotes key personnel (Lead Investigator and CEO). This content structure—announcing clinical trial results via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is focused on clinical data updates rather than comprehensive financial performance (10-K) or a formal regulatory filing summary (RNS), and it is not a transcript (CT) or a formal investor presentation (IP), the most fitting category for a major clinical data announcement that is not a full financial report is the Earnings Release (ER), as these often accompany or precede quarterly financial discussions, or the Regulatory Filing (RNS) as a general announcement. Given the focus is purely on clinical trial results and regulatory context (EMA approval mentioned), and it is a 'Press release', it functions as a significant corporate update. However, ER is typically for financial results. Since this is a scientific/clinical update press release, and it doesn't fit the specific definitions for AR, IP, or LTR, it falls best under the general announcement category, RNS, or potentially ER if it's tied to a reporting cycle. Given the nature of biotech press releases announcing trial data, RNS (Regulatory Filings/General Announcement) is the safest fit if ER is reserved strictly for financial performance summaries. Since it is a press release announcing significant corporate/clinical news, RNS is appropriate as a broad regulatory/corporate announcement category.
2022-10-26 English
Issue and re-purchase of class C shares for shareholder program and incentive program
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated October 20, 2022, announcing the 'Issue and re-purchase of class C shares for shareholder program and incentive program.' This action involves the issuance and subsequent repurchase of shares, which directly relates to changes in the company's capital structure and share count, often executed under authorizations from a general meeting. This activity falls under the definition of Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since the core action is the issuance and repurchase of shares related to incentive programs, 'Share Issue/Capital Change' (SHA) is the most precise fit, as it deals directly with the mechanics of share issuance and capital structure modification, rather than just general financing activities (CAP). It is not a dividend notice (DIV), a director's dealing (DIRS), or a general regulatory filing (RNS).
2022-10-20 English
Emission och återköp av C-aktier för aktieägarprogram och incitamentsprogram
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated October 20, 2022, detailing a decision by the Board of Directors to execute a new issuance (nyemission) and subsequent repurchase of C-shares related to shareholder and incentive programs (Board SHP 2022 and Co-worker LTIP 2022). This action directly involves changes to the company's capital structure (issuance and repurchase of shares) to fulfill obligations under employee incentive plans. This aligns precisely with the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core action is the issuance and immediate repurchase of shares tied to compensation/incentive plans, 'SHA' (Share Issue/Capital Change) is highly relevant, but 'CAP' (Capital/Financing Update) is often used for these structured capital movements. Given the explicit mention of 'nyemission' (new issue) and 'återköp' (repurchase) of shares, SHA is the most specific fit, although CAP is also plausible. I will select SHA as it describes the mechanism (share change) rather than the broader context (financing update). The document is short and appears to be the primary announcement, not just a notice of publication.
2022-10-20 Swedish
Kommuniké från extra bolagsstämma i Oncopeptides AB (pupl)
Share Issue/Capital Change Classification · 1% confidence The document is titled "Kommuniké från extra bolagsstämma i Oncopeptides AB (pupl)" which translates to "Communication from the Extraordinary General Meeting in Oncopeptides AB (publ)". It details the decisions made at this meeting, specifically mentioning the authorization of the board regarding new share issues (nyemission av aktier). This content directly relates to shareholder decisions and corporate governance actions taken at a general meeting. While it discusses capital structure changes (CAP), the primary context is the outcome of the shareholder meeting. Since the document reports the decisions made at a general meeting, the most appropriate classification is AGM-R (AGM Information), as an Extraordinary General Meeting (EGM) falls under the scope of general meetings, even if the specific action is capital-related. It is not a formal proxy statement (PSI) or a general capital announcement (CAP), but a record of meeting outcomes.
2022-09-23 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.